Terms: = Pancreatic cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
807 results:
1. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T; Nguyen A; Misleh J; Cline VJ; Johns M; Shumway N; Paulson S; Siegel R; Larson T; Messersmith W; Richards D; Chaves J; Pierce E; Zalupski M; Sahai V; Orr D; Ruste SA; Haun A; Kawabe T
Eur J Cancer; 2024 Apr; 201():113950. PubMed ID: 38422585
[TBL] [Abstract] [Full Text] [Related]
2. Irreversible Electroporation-Induced Inflammation Facilitates Neutrophil-Mediated Drug Delivery to Enhance pancreatic cancer Therapy.
Huang T; Wen X; Liang Y; Liu X; Zhao J; Long X
Mol Pharm; 2024 Apr; 21(4):1998-2011. PubMed ID: 38412284
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.
Qiu X; Lu C; Sha H; Zhu Y; Kong W; Tong F; Wang Q; Meng F; Liu B; Du J
Front Immunol; 2024; 15():1210859. PubMed ID: 38361920
[TBL] [Abstract] [Full Text] [Related]
4. Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
Skipper MT; Birkebæk N; Jensen RB; Rank CU; Tuckuviene R; Wehner PS; Lambine TL; Hørlyck A; Schmiegelow K; Frandsen TL; Andrés-Jensen L; Albertsen BK
Eur J Haematol; 2024 Jun; 112(6):944-956. PubMed ID: 38351310
[TBL] [Abstract] [Full Text] [Related]
5. Therapy-induced senescent cancer cells exhibit complement activation and increased complement regulatory protein expression.
Abu-Humaidan AH; Ismail MA; Ahmad FM; Al Shboul S; Barham R; Tadros JS; Alhesa A; El-Sadoni M; Alotaibi MR; Ababneh NA; Saleh T
Immunol Cell Biol; 2024 Apr; 102(4):240-255. PubMed ID: 38265162
[TBL] [Abstract] [Full Text] [Related]
6. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract] [Full Text] [Related]
7. The relationship between DNA mismatch repair gene and other prognostic parameters in pancreatic adenocarcinoma.
Urganci N; Kepil N; Ergun S; Bakkaloglu OK
J Surg Oncol; 2024 Apr; 129(5):876-884. PubMed ID: 38173349
[TBL] [Abstract] [Full Text] [Related]
8. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
9. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected pancreatic cancer.
Murthy P; Zenati MS; AlMasri SS; DeSilva A; Singhi AD; Paniccia A; Lee KK; Simmons RL; Bahary N; Lotze MT; Zureikat AH
J Natl Compr Canc Netw; 2023 Dec; 22(1D):e237070. PubMed ID: 38150819
[TBL] [Abstract] [Full Text] [Related]
10. The association between food access and frailty among older adults with gastrointestinal malignancies-The CARE Registry.
Fowler ME; Harmon C; Sharafeldin N; Baker E; Oates G; Nassel A; Clausing D; Giri S; Williams GR
Cancer; 2024 Apr; 130(7):1083-1091. PubMed ID: 38059840
[TBL] [Abstract] [Full Text] [Related]
11. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
[TBL] [Abstract] [Full Text] [Related]
12. Targeted delivery of genistein for pancreatic cancer treatment using hyaluronic-coated cubosomes bioactivated with frankincense oil.
Sallam NG; Boraie NA; Sheta E; El-Habashy SE
Int J Pharm; 2024 Jan; 649():123637. PubMed ID: 38008234
[TBL] [Abstract] [Full Text] [Related]
13. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract] [Full Text] [Related]
14. Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: the CHAMP study.
Hau SO; Svensson M; Petersson A; Eberhard J; Jirström K
BMC Cancer; 2023 Nov; 23(1):1074. PubMed ID: 37936126
[TBL] [Abstract] [Full Text] [Related]
15. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.
Xu C; Zhu M; Wang Q; Cui J; Huang Y; Huang X; Huang J; Gai J; Li G; Qiao P; Zeng X; Ju D; Wan Y; Zhang X
J Nanobiotechnology; 2023 Nov; 21(1):410. PubMed ID: 37932752
[TBL] [Abstract] [Full Text] [Related]
16. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.
Chiorean EG; Picozzi V; Li CP; Peeters M; Maurel J; Singh J; Golan T; Blanc JF; Chapman SC; Hussain AM; Johnston EL; Hochster HS
Cancer Med; 2023 Oct; 12(20):20353-20364. PubMed ID: 37840530
[TBL] [Abstract] [Full Text] [Related]
18. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic pancreatic Adenocarcinoma.
Huffman BM; Feng H; Parmar K; Wang J; Kapner KS; Kochupurakkal B; Martignetti DB; Sadatrezaei G; Abrams TA; Biller LH; Giannakis M; Ng K; Patel AK; Perez KJ; Singh H; Rubinson DA; Schlechter BL; Andrews E; Hannigan AM; Dunwell S; Getchell Z; Raghavan S; Wolpin BM; Fortier C; D'Andrea AD; Aguirre AJ; Shapiro GI; Cleary JM
Clin Cancer Res; 2023 Dec; 29(24):5047-5056. PubMed ID: 37819936
[TBL] [Abstract] [Full Text] [Related]
19. Response of Locally Advanced pancreatic cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and Clinical Outcome.
Sharma NR; Lo SK; Hendifar A; Othman MO; Patel K; Mendoza-Ladd A; Verco S; Maulhardt HA; Verco J; Wendt A; Marin A; Schmidt CM; diZerega G
Pancreas; 2023 Mar; 52(3):e179-e187. PubMed ID: 37782888
[TBL] [Abstract] [Full Text] [Related]
20. [
Chan CY; Chen Z; Guibbal F; Dias G; Destro G; O'Neill E; Veal M; Lau D; Mosley M; Wilson TC; Gouverneur V; Cornelissen B
J Nucl Med; 2023 Dec; 64(12):1965-1971. PubMed ID: 37770109
[TBL] [Abstract] [Full Text] [Related]
[Next]
